New treatments for heart and kidney problems in type 1 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests new treatments for people with long-standing type 1 diabetes who also have early signs of heart or kidney disease. The goal is to see if these treatments can help protect the heart and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 diabetes diagnosed within the first year of needing insulin, or if over age 35, you have lab evidence.
- You are between 18 and 75 years old.
- You have had type 1 diabetes for more than 10 years.
- Your blood sugar control (HbA1c) is between 7% and 10%.
- You have either early kidney damage (with specific lab numbers) or early heart failure signs (based on a blood test).
- You do not take certain medications like GLP-1 receptor agonists or immunosuppressants recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial tests a medication, finerenone, to help protect kidney function and prevent heart failure in people with type 2 diabetes and chronic kidney disease. If you have diabetes and kidney problems, this medicine might slow down further kidney damage.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.